BRCA1 and ovarian carcinoma: The discovery that ovarian cancer cells harboring mutations in the homologous recombination repair (HRR) genes BRCA1 and BRCA2 exhibit synthetic lethality when treated with poly adenosine diphosphate (ADP)-ribose polymerase inhibitors (PARPi) has further expanded the application of PARPi in the clinic beyond BRCA1/2 mutant cancers, with efforts to further identify genome-wide synthetic lethal vulnerabilities to this class of drugs [2].